MiMedx Group, Inc $MDXG Shares Sold by Turtle Creek Wealth Advisors LLC

Turtle Creek Wealth Advisors LLC trimmed its position in MiMedx Group, Inc (NASDAQ:MDXG) by 8.3% in the second quarter, Holdings Channel reports. The firm owned 166,700 shares of the company’s stock after selling 15,000 shares during the quarter. Turtle Creek Wealth Advisors LLC’s holdings in MiMedx Group were worth $1,019,000 as of its most recent SEC filing.

A number of other hedge funds have also bought and sold shares of MDXG. CWM LLC grew its stake in MiMedx Group by 63.8% in the second quarter. CWM LLC now owns 4,857 shares of the company’s stock worth $30,000 after purchasing an additional 1,892 shares in the last quarter. Virtus Advisers LLC acquired a new position in MiMedx Group in the first quarter worth about $40,000. Legato Capital Management LLC acquired a new position in MiMedx Group in the first quarter worth about $101,000. AQR Capital Management LLC lifted its holdings in MiMedx Group by 42.6% in the first quarter. AQR Capital Management LLC now owns 14,374 shares of the company’s stock worth $109,000 after acquiring an additional 4,296 shares during the last quarter. Finally, Sowell Financial Services LLC acquired a new position in MiMedx Group in the first quarter valued at approximately $115,000. 79.15% of the stock is currently owned by institutional investors and hedge funds.

MiMedx Group Stock Up 2.0%

Shares of MiMedx Group stock opened at $6.71 on Thursday. MiMedx Group, Inc has a twelve month low of $5.59 and a twelve month high of $10.14. The company has a current ratio of 4.39, a quick ratio of 3.90 and a debt-to-equity ratio of 0.08. The stock has a market capitalization of $992.81 million, a price-to-earnings ratio of 31.95 and a beta of 1.73. The business’s 50 day simple moving average is $7.05 and its 200-day simple moving average is $6.81.

MiMedx Group (NASDAQ:MDXG) last posted its earnings results on Monday, November 13th. The company reported ($0.03) EPS for the quarter. MiMedx Group had a net margin of 8.84% and a return on equity of 23.03%. The business had revenue of $67.69 million during the quarter. Equities research analysts forecast that MiMedx Group, Inc will post 0.3 earnings per share for the current year.

Analysts Set New Price Targets

A number of analysts have recently weighed in on the company. Weiss Ratings reiterated a “hold (c)” rating on shares of MiMedx Group in a research report on Wednesday, October 8th. Cantor Fitzgerald increased their price target on MiMedx Group from $11.00 to $12.00 and gave the stock an “overweight” rating in a research report on Thursday, July 31st. Finally, Wall Street Zen upgraded MiMedx Group from a “hold” rating to a “strong-buy” rating in a research report on Saturday, August 2nd. One analyst has rated the stock with a Buy rating and one has given a Hold rating to the stock. According to MarketBeat, MiMedx Group has a consensus rating of “Moderate Buy” and a consensus target price of $12.00.

MiMedx Group Profile

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue’s inherent biological properties and regulatory proteins.